Company:Â Vanda Pharmaceuticals
Starting stock price: $24.83
Ending stock price: $6.88
Percent Change: -72.29%
Details: Vanda Pharmaceuticals has three in-development candidates, all focused on nervous system disorders. In September 2007, it filed a NDA for its antipsychotic med iloperidone. In a clinical trial the drug showed efficacy against schizophrenia symptoms but some developed an irregular heartbeat; the company plans to couple genetic testing with its drug to identify those likely to experience the heart problem. Its two other possibles are targeted at sleep and mood problems. One is in Phase III and the other recently wrapped up a Phase II study.
More News:
Vanda gains on late-stage sleep trial data. Report
Read more on
